SIR, Several authors have reported the possible association between rheumatoid arthritis (RA) and the HLA-DR4
antigen.'`7 The most recent report has appeared in your columns.7 Some of the studies suggested that RA patients with HLA-DR4 more often had positive latex tests for rheumatoid factor, with higher titres than the other patients.3`6 HLA-DR4 might thus operate in relation to IgM rheumatoid factor production rather than rheumatoid arthritis. As healthy persons have low amounts of rheumatoid factors in their sera,' we therefore investigated whether those with HLA-DR4 had more rhematoid factors than the others.
Rheumatoid factors were measured quantitatively in the sera of 77 unrelated, healthy persons who had been tissue typed before (mean age 45 years, range 25-75; 47 were women). We used a recently developed highly sensitive, enzyme linked, solid phase immunoassay measuring IgM rheumatoid factors with human IgG as an antigen. There are 5 dilutions in the normal range and the results obtained with this assay show an excellent correlation with those obtained with the latex test used in our laboratory6 (to be published). The overall incidence of HLA-DR4 was 21% in the 77 healthy controls; the 55 persons with 'low normal' titres had rather a higher frequency of HLA-DR4 (24%) than the 22 with 'high normal' titres (14%; NS). Although only small numbers of normals were tested, these results do not suggest that DR4 influences rheumatoid factor titres in healthy persons. Similarly, Rodriguez et al.' did not find a relationship between HLA-DR4 and in-vitro IgM rheumatoid factor production in normals. In RA the relationship between DR4 and rheumatoid factors has not always been found; the study by Gran et al.7 is the latest in this line. The difference might be, as these authors suggest, in the selection of the patients with seronegative RA during the different studies.
ESR in polymyalgia rheumatica and giant cell arteritis SIR, The recent report by Ellis and Ralston' on the ESR in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) raises some interesting points. They found a normal ESR in 22-5% of cases at presentation, which is, as they state, a much higher incidence than has been found in other series.2 The value they adopted as elevated was 30 mm/h, and they quote that this was one of the diagnostic criteria which we used in our study of 108 patients with PMR and/or GCA. 6 In fact the full version of our criteria read:'An ESR of 30 mm/h or greater or a C-reactive protein of greater than 6-4 ,ug/100 ml.' We did not come across one patient with clinical evidence of PMR and /or GCA with an ESR or CRP which was not raised on at least one occasion. In one case the ESR was normal on the 2 occasions it was measured (20 mm/h and 17 mm/h), but the CRP was elevated at ,ug/100 ml. The ESR returned to below 20 mm/h on at least one occasion in all except 3 of the 101 cases in which a follow-up result was available, The elevation of the ESR was only modest in these 3 cases (32,28,24 mm/h) and could be explained by continuing activity of the disease (2 cases) and a long-standing benign monoclonal gammopathy. The lowest recorded ESR was below 15 mm/h in 95% of the 101 cases and 10 mm/h or less in 76%of the patients. However, like Ellis and Ralston we observed several patients who were successfully managed on their symptoms alone and do not advocate that the dose of prednisone should be adjusted with the sole aim of keeping the ESR at a normal level. This may not prevent complications. One patient developed permanent loss of vision in one eye 2 months after the institution of corticosteroids, when she was completely symptom-free with an ESR of 3 mm/h. However, we feel that the ESR remains a most useful investigation in the diagnosis of PMR/GCA and recommend that, if a normal result is obtained initially, the ESR should be repeated at short intervals, as it may well be elevated subsequently. We should also recommend that the CRP should be measured in the suspected case with a normal ESR. Statistical power calculations SIR, When papers report a difference between 2 groups of patients they are expected to give the probability that such a difference (or an even bigger one) could have occurred by chance (the p value). Reports of negative findings may provide important information, and these too should be supported by statistical calculations-in this case giving the probability that the failure to find a difference between patient groups may have occurred purely by chance (the 'power' of the investigation).
In the Annals for June 1983 you published 2 investigations which reported negative findings: the failure of hyperuricaemia to contribute to increased risk of vascular disease' and the failure of the type of onset of rheumatoid arthritis to predict subsequent outcome.2 The conclusions of both these papers are of interest, but they would have been strengthened by the inclusion of power calculations.' numerous, references up to date from all countries, mostly in English. One criticism could be that 'Still's syndrome' is called juvenile rheumatoid arthritis, 'the equivalent form of rheumatoid disease' below 16 years of age. The book in general shows that the disorder otherwise seems much the same as we see in our patients here in Great Britain, and gives good wide references from the world's recent literature on the subject.
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